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Abstract
Background: Xenotropic murine leukemia virus-related virus (XMRV), a novel human retrovirus originally identified in
prostate cancer tissues, has recently been associated with chronic fatigue syndrome (CFS), a disabling disease of unknown
etiology affecting millions of people worldwide. However, several subsequent studies failed to detect the virus in patients
suffering from these illnesses or in healthy subjects. Here we report the results of efforts to detect antibody responses and
viral sequences in samples from a cohort of German CFS and relapsing remitting multiple sclerosis (MS) patients with
fatigue symptoms.
Methodology: Blood samples were taken from a cohort of 39 patients fulfilling the Fukuda/CDC criteria (CFS), from 112
patients with an established MS diagnosis and from 40 healthy donors. Fatigue severity in MS patients was assessed using
the Fatigue Severity Scale (FSS). Validated Gag- and Env-ELISA assays were used to screen sera for XMRV antibodies. PHA-
activated PBMC were cultured for seven days in the presence of IL-2 and DNA isolated from these cultures as well as from
co-cultures of PBMC and highly permissive LNCaP cells was analyzed by nested PCR for the presence of the XMRV gag gene.
In addition, PBMC cultures were exposed to 22Rv1-derived XMRV to assess infectivity and virus production.
Conclusion: None of the screened sera from CFS and MS patients or healthy blood donors tested positive for XMRV specific
antibodies and all PBMC (and PBMC plus LNCaP) cultures remained negative for XMRV sequences by nested PCR. These
results argue against an association between XMRV infection and CFS and MS in Germany. However, we could confirm that
PBMC cultures from healthy donors and from CFS patients can be experimentally infected by XMRV, resulting in the release
of low levels of transmittable virus.
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Introduction
Retroviruses are able to induce immunodeficiency, malignant
transformation and neurologic diseases. In addition to HTLV and
HIV, evidence for a third exogenous human retrovirus was
published in 2006. This previously unknown gammaretrovirus was
identified in prostate cancer patients and named xenotropic
murine leukemia virus-related virus (XMRV) based on its high
sequence similarity to endogenous xenotropic murine leukemia
viruses [1]. In the initial report and in a recently published study
[2] XMRV infection strongly correlated with a presumably
impaired antiretroviral response due to a genetic polymorphism
in the RNASEL gene encoding a type I interferon-induced
endonuclease. A potential role of XMRV in the etiology of
prostate cancer was further strengthened by a report from
Schlaberg and coworkers identifying the virus in the epithelial
tumor cells of 27% of sporadic prostate cancer patients [3]
although no association with the RNASEL polymorphism was
found but rather a positive correlation with tumor grade. In
contrast to these reports involving American patients, studies using
European cohorts found no [4,5] or a very low prevalence [6] of
XMRV in prostate cancer tissues.
In a recent Science publication, XMRV was linked to a
completely different disease: chronic fatigue syndrome (CFS), also
known as myalgic encephalomyelitis (ME) [7]. The retrovirus was
detected in 68 of 101 patients tested and in 3.7% of healthy
controls. Infection of blood cells was demonstrated, virus was
transmittable to indicator cells or to fresh PBMC and plasma
samples from CFS patients were shown to contain virus-specific
antibodies [7]. CFS is a disease characterized by a long-lasting
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disabling fatigue accompanied by physical symptoms that
resemble a severe flu-like illness [8]. Several viral (including
retroviral) or microbial agents have been suggested to be involved
in CFS, particularly as the onset of symptoms in many patients
begin with an infectious illness. Furthermore, CFS can occur at
any age, affecting both children and adults but for unknown
reasons has a higher prevalence in women than in men [9].
Multiple Sclerosis (MS) is a common chronic neuroimmunolo-
gic disorder, whose etiology is not yet fully understood.
Characterized by lymphocytic infiltration and damage of myelin
sheaths and axons in the early stages, the disease can progress to
extensive neurodegeneration with severe disability in later stages
[10]. Although fatigue is one of the most common symptoms in
MS, being reported by more than 90% of patients [11], the
biological cause of MS related fatigue remains unknown. It shares
many of the hallmark symptoms of CFS and has a substantially
negative impact on the quality of life of those affected [12].
Due to the potential implication of these findings, not only for
the estimated 17 million people worldwide suffering from CFS but
also for public health, including blood safety, a thorough
investigation of the overall prevalence and association of XMRV
with CFS is crucial. Following shortly the initial publication by
Lombardi et al. [7], three European studies failing to detect
XMRV in blood samples from independent cohorts of CSF
patients were published [13,14,15]. However, these reports are
severely criticized because the PCR analyses were performed using
DNA from unstimulated PBMCs: Gammaretroviruses such as
XMRV are assumed to productively infect only dividing cells [16]
and activation of the cells allowing virus proliferation in vitro might
therefore be necessary for successful detection.
In the present report we have analyzed samples from well-
characterized German cohorts of CFS patients and MS patients
with fatigue for evidence of XMRV. In addition, the ability of
XMRV to infect and establish productive replication in PBMC
from CFS patients and healthy blood donors was evaluated.
Results
XMRV antigen ELISA
Infection with a novel retrovirus such as XMRV would be
expected to result in the induction of an immune response,
particularly with antibodies specific for the viral Env and Gag
proteins. Envelope specific antibodies have recently been shown to
be present in the plasma of XMRV-infected CFS patients and sera
from XMRV-positive prostate cancer patients were shown to
neutralize the virus [2,7]. We therefore analyzed sera from 36 CFS
patients, 112 multiple sclerosis patients and 27 healthy individuals
for serological evidence of XMRV infection (Table 1). Initially, an
ELISA using recombinant XMRV Env proteins as antigen was
used as described previously [5]. Although panels of XMRV
positive human specimens were not available this assay has
recently been validated in a blinded fashion using goat polyclonal
anti-MuLV gp70 antisera and corresponding goat control sera
[17]. At a 1:200 dilution, none of the CFS or healthy control
samples tested positive, whereas four of the MS sera tested weakly
positive (Fig. 1A). However, when subsequently examined by
immunofluorescence for binding to HEK 293T cells transfected
either with a codon-optimized XMRV Env expression construct
or with the XMRV full-length VP62 molecular clone, these
samples were found to be negative. As positive control, the
polyclonal mouse antiserum used in the ELISA gave a strong
signal in cells transfected with either expression vector (data not
shown).
Antibody responses to retroviral Gag proteins are frequently
used to screen for infection. We therefore developed an antigen
capture ELISA to detect XMRV Gag-specific antibodies that had
a markedly reduced background compared to the previously used
Gag-ELISA where antigen was adhered directly to the microtiter
plate well [5]. The specificity and sensitivity of the new capture
ELISA was demonstrated by a titration of a positive control goat
serum (Fig. 1B). Using this assay, one of the 36 CFS patients
examined, one of the healthy donors (Fig. 1C, upper panel) but
none of the 112 MS patients (Fig. 1C, lower panel) were slightly
reactive. However, these weakly positive sera failed to react with
HEK 293T cells expressing the XMRV Gag protein or transfected
with the XMRV VP62 molecular clone by immunofluorescence
(data not shown). In summary, sera from neither 36 CSF and 112
MS patients nor from 27 healthy controls tested positive for
antibodies to XMRV Env and Gag proteins (Table 1).
Provirus PCR in cultured PBMC
MLVs and other closely related retroviruses are unable to cross
the nuclear pore complex for integration into the genomic DNA of
the host, relying instead on mitosis to access the host cell
chromosomes [18]. In order to improve the sensitivity of the test
we therefore activated PBMC with PHA and cultured in the
presence of IL-2 for seven days prior to DNA isolation, a process
likely to increase the number of XMRV-infected cells. PBMC
from 39 CFS patients, 50 multiple sclerosis patients with high
fatigue scores (FSS median 4.7, range 2.9-7.0) and 30 healthy
volunteers were analyzed, of which the corresponding sera from
36 CFS patients, all 50 MS patients and 17 of the 30 healthy
donors had already been tested by ELISA (Fig. 1). The integrity of
the isolated DNA and the absence of PCR inhibitors were
confirmed by amplification of GAPDH sequences (Fig. 2). PBMC
culture and DNA preparations were performed in laboratories of
the Charite´ clinic and the PCRs were run at the Robert Koch
Institute in a blinded manner. First, nested PCRs to detect proviral
XMRV gag sequences with high sensitivity and specificity [5] were
run in parallel by two operators in different laboratories in a
Table 1. Overview of patient samples and test results1.
Patient cohort ELISA Env ELISA Gag IFA2
Nested PCR of PBMC
DNA
RT activity
in co-culture
Nested PCR of LNCaP DNA
from co-culture
CFS 0/36 1/36 0/1 0/39 0/10 0/10
MS 4/112 0/112 0/4 0/50 n.d. n.d.
Healthy 0/27 1/27 0/1 0/30 n.d. n.d.
1Number of positives/total number of patient samples tested.
2Only samples above the ELISA cut-offs were assayed.
n.d. = not done.
doi:10.1371/journal.pone.0015632.t001
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blinded fashion and all DNA samples were found to be consistently
negative (Table 1, see Fig. 2 for representative results).
Furthermore, when DNA samples from a random selection of
13 CFS and 20 healthy donor were tested using an alternative
nested PCR described by Urisman et al [1] the results were also
negative (data not shown).
Co-culture of PBMC with LNCaP cells
Patient cells were cocultivated with the highly susceptible
prostate cancer cell line LNCaP [19] in an attempt to expand, as
reported by Lombardi et al [7], possible low levels of infection.
Activated PBMC from 10 randomly chosen CFS patients and
from 10 healthy donors were added at day three to LNCaP cells
for three hours to allow virus transmission. Supernatant from
chronically infected 22Rv1 cells was added to separate LNCaP cell
cultures as a positive control. After seven days, DNA was isolated
from the LNCaP cells and tested by nested XMRV-Gag PCR [5].
The PBMC from neither the 10 CFS patients nor the 10 healthy
donors transmitted XMRV to the LNCaP cells (Table 1), whereas
incubation with 22Rv1 supernatant resulted in the expected
infection of the indicator cells (Fig. 3). Contamination of this DNA
preparation with murine genomic DNA or with the pcDNA3.1-
VP62 plasmid was ruled out using a PCR designed to detect
murine DNA (kindly provided by B. Klempa) and a nested-PCR
able to detect less than 10 copies of the pcDNA3.1-VP62 plasmid
in 200ng of human DNA (data not shown). This control was
necessary because the plasmid is used frequently in many
laboratories including our own. Consistent with the PCR results,
RT activity was only detected in the supernatants of LNCaP cells
incubated with 22Rv1 cell supernatant (Table 1).
Infection of PBMCs with XMRV
We next addressed the question as to whether PBMCs from
CFS patients and healthy donors are susceptible to XMRV
infection and if so, whether infectious virus is released. At day 3
post-activation, PBMCs from a randomly selected subset of 5 CFS
patients and 5 healthy donors were incubated with cell-free
supernatant from 22Rv1 cells or with the same supernatant
previously subjected to heat inactivation. All supernatants were
treated with DNase I to exclude carryover of 22Rv1 cell genomic
DNA. LNCaP cells were also incubated with the supernatants as a
positive control.
After seven days in culture, DNA was isolated and subjected to
diagnostic nested PCR. XMRV provirus was detected in DNA
from each of the 10 infected PBMC samples, whereas the samples
incubated with heat-inactivated virus remained negative (Table 2
and Fig. 4A). DNA integrity was confirmed by amplification of the
GAPDH gene and no contamination with mouse genomic DNA
or with the pcDNA3.1-VP62 plasmid was detected. RT activity,
indicating the release of viral particles, was detected in 9/10
supernatants (4/5 CFS and 5/5 healthy donors) collected at 7 days
post infection from the infected PBMC (Table 2). Except one CFS
patient (CFS-7) which supernatant was RT negative the measured
RT activities in PBMC supernatants of infected CFS patients and
healthy donors were between 136 and 1218.5 mU/ml (median of
469 mU/ml). Taking into account the 1:100 pre-dilution,
945.3 mU/ml of RT activity were present in the supernatant of
the infected LNCaP cells. Thus, PMBC either from CFS patients
or from healthy donors released about 2000-fold less viral particles
than LNCaP cells in our setting. Supernatants of PBMCs or
LNCaP cells incubated with heat-inactivated 22Rv1 supernatant
remained negative for RT activity. Therefore, PBMCs can be
infected by XMRV and cells carrying the provirus are present and
release viral particles after a week.
Finally, susceptible LNCaP cells were exposed to PBMC
supernatants taken at 7 days post infection to determine whether
the newly produced virus particles are themselves infectious.
XMRV could be detected by diagnostic PCR in DNA isolated
from LNCaP cells a week after exposure to supernatants from
Figure 2. Diagnostic PCR of activated PBMC from CFS and MS patients and healthy donors. Representative results of nested XMRV PCRs
with template DNAs from activated PBMCs after 7 days of culture. Samples from 5 CFS patients (lanes 1–5), 5 MS patients (lanes 6–10) and 5 healthy
donors (HD, lanes 11–15) are shown. 200 ng of human genomic DNA spiked with 14 pg of 22Rv1 DNA (genome equivalent of approximately two
cells) were used as positive control (lane 16). Results of corresponding single round PCRs for GAPDH as control for DNA integrity and absence of PCR
inhibitors are shown in the lower panel. M =100 bp marker.
doi:10.1371/journal.pone.0015632.g002
Figure 1. Serological assays. ELISAs with recombinant XMRV proteins were used to detect specific humoral responses. The cut-off was calculated
as the mean of all sera from healthy controls plus three times the standard deviation. (A) Results of an XMRV Env antibody ELISA with sera from 36
CFS patients and 17 healthy controls (upper panel) and 112 MS patients and 10 healthy controls (lower panel) identified after unblinding. Sera were
incubated at a dilution of 1:200. (B) Titration of positive control goat sera versus recombinant Gag protein captured by the monoclonal anti-MLV Gag
antibody R187. (C) Capture ELISA for the detection of XMRV anti-Gag antibodies in CFS (upper panel) and MS (lower panel) patient sera and healthy
controls (gray bars in both panels). Human sera were diluted 1:200 in blocking buffer.
doi:10.1371/journal.pone.0015632.g001
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XMRV-infected PBMC from 2/5 CFS patients and 4/5 healthy
donors (Table 2 and Fig. 4B). Supernatants from none of the
PBMC cultures that were initially incubated with heat inactivated
22Rv1 supernatants were able to infect LNCaP cells. The integrity
of the isolated LNCaP cell DNA was also confirmed by GAPDH
amplification and the absence of XMRV plasmid DNA and
mouse genomic DNA was demonstrated by PCR (data not shown).
Furthermore, RT activity was detected in the supernatant from 5
of the 6 LNCaP cell cultures that tested positive for XMRV
infection by PCR (Table 2). In summary, these results demonstrate
that cells present in human PBMC cultures can be productively
infected by XMRV and release infectious virus particles.
Discussion
CFS/ME is a multifaceted illness with an unknown etiology and
a diagnosis based on the careful exclusion of other conditions and
diseases with similar symptoms including HIV infection and
multiple sclerosis [9,20]. Recently, the novel human retrovirus
XMRV was reported to be detectable in the lymphocytes of two-
thirds of American patients fulfilling the 1994 international CFS
case definitions [8] and the 2003 Canadian Consensus Criteria, as
well as in lymphocytes from almost 4% of healthy controls [7].
This association raises the obvious possibility that XMRV may be
a causative agent of CFS or a contributing factor in the
pathogenesis of the disease. Furthermore, the authors found
evidence for an XMRV-specific antibody response in infected CFS
patients, a finding that would be expected as no closely related
endogenous human retroviral sequences are known that might
induce tolerance. Specific antibodies to the virus have also been
identified in the sera from XMRV-positive prostate cancer
patients [2] and more recently in experimentally infected
macaques [21].
Interestingly, patients suffering from the common neuroimmu-
nologic disorder multiple sclerosis [10] also show fatigue symptoms
that closely resemble in part those of CFS. Although this MS-
related fatigue [11] is a major contributor to the reduced quality of
life suffered by MS patients, the biological cause remains
unknown. However, the similar clinical presentation of CFS and
MS-related fatigue suggests a possible common etiology. That
retroviruses may be an underlying cause for the neuroimmuno-
logical dysfunctions that appear with both diseases has already
been proposed [22,23,24,25]. In this regard it should also be kept
in mind that HTLV I is able to induce Tropical Spastic
Paraparesis (TSP) a neuronal degenerative disease in some of
the infected individuals and leukemia or lymphomas in others
[26]. We therefore attempted to find evidence for XMRV
infection of CFS and MS patients by screening their sera by
ELISA. The CFS patients, recruited from the Charite´, were
diagnosed according to the 1994 international CFS case
definitions. And the MS patients, recruited from the Charite´’s
NCRC outpatient clinic, were diagnosed with definite relapsing
remitting multiple sclerosis according to the current panel criteria
[27]. In addition to the 36 CFS patients and 112 MS patients, 27
healthy individuals donated serum for testing. Using a previously
described and evaluated Env-ELISA [5,17] and a newly developed
capture Gag-ELISA we found no evidence for specific seroreac-
tivity among any of the human samples screened. These results are
Figure 3. Lack of infection of XMRV susceptible LNCaP cells by co-culture with activated PBMCs. PCR results with isolated LNCaP cell
DNA after co-culture with PBMCs from CFS patients (lane 1–5) and healthy donors (lanes 6–10). Five representative samples out of 10 co-cultures for
each group are shown. As control, LNCaP cells were infected with XMRV-containing supernatant from 22Rv1 cells (lane 12). A water-only control (no
template control, NTC) was run in lane 11. Results of the GAPDH PCR with the same samples are shown in the lower panel. M = 100 bp marker.
doi:10.1371/journal.pone.0015632.g003
Table 2. Infection of human blood cells with XMRV from the 22Rv1 cell line.
PBMC culture LNCaP culture
Infection with: Diagnostic PCR RT-activity Diagnostic PCR RT-activity
CFS patients SN 5/5 4/5 2/5 2/5
SN heat inact. 0/5 0/5 0/5 0/5
Healthy donors SN 5/5 5/5 4/5 3/5
SN heat inact. 0/5 0/5 0/5 0/5
SN= Supernatant.
doi:10.1371/journal.pone.0015632.t002
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in stark contrast with the original description of a significant
association between XMRV-infection and CFS [7] but are in
agreement with a more recent study in which plasma samples from
CFS cases in the USA were tested and found to be negative [17].
In addition to the serological assays, we used nested PCR to test
DNA from in vitro activated PBMCs for the presence of proviral
XMRV. Activation by PHA and culture in the presence of IL-2 is
likely to increase the number of infected cells by stimulating virus
expression and the infectivity of the cells, thereby increasing the
detection sensitivity. Indeed, expression of XMRV protein has
been described in activated T- and B-cells [7]. Nevertheless, even
after stimulation for seven days, none of the 119 PBMC cultures
yielded detectable XMRV sequences (39 from CFS patients, 50
from MS patients and 30 from healthy blood donors). Four
previous studies have already reported negative results using DNA
isolated from the unstimulated PBMCs of more than 410 CFS
patients [13,14,15,17], contradicting the hypothesis that most
individuals affected by CFS carry the virus. Moreover, in a recent
report addressing XMRV in Danish patients with MS no XMRV
has been found as well. In this study single-round PCRs for gag and
env sequences with DNA from unstimulated PBMC were used
[28]. Our nested PCR set up consistently detects 10 proviral
XMRV sequences in 200-800ng of human DNA [5] and as 200ng
DNA corresponds to a genome equivalent of about 33,300 cells
(6pg DNA/cell), the test, performed in duplicate, has a detection
limit of one provirus in at least 3,300 PBMC. It should be noted
that although a very low ratio of infected cells could result in
inconsistent or even negative PCR results, such low ratios would
be inconsistent with published data demonstrating that a
considerable proportion of activated PBMCs from XMRV-
positive CFS patients express viral proteins, detected by intracel-
lular flow cytometry [7]. To minimize the possibility of failing to
Figure 4. Human PBMC cultures are susceptible to productive infection by XMRV. (A) Detection of proviral XMRV sequences by nested
PCR in DNAs of PBMC from 5 CSF patients (lanes 1–5) and 5 healthy donors (HD, lanes 6–10) infected for a week with DNase I treated (left hand panel)
or DNase I treated and heat-inactivated (right hand panel) supernatants from the XMRV producing 22Rv1 cell line. The no template control (NTC) is in
lane 11. DNA prepared from 22Rv1 cells was used as a positive control (lane 12, left panel). Results of a single round PCR for GAPDH are depicted
underneath. (B) On the day of DNA isolation, supernatants from the infected PBMC cultures were used to test for virus transmission to LNCaP
indicator cells. The results of a nested XMRV PCR with DNA prepared from the exposed LNCaP cells a week after incubation with the PBMC
supernatants are shown (lanes 1–10). The control set up was the same as described above (lanes 11 and 12). M =100 bp marker. The entire
experiment has been repeated twice with similar results.
doi:10.1371/journal.pone.0015632.g004
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detect a provirus due to primer mismatch, 33 samples were also
run with the nested PCR primers and conditions previously
published by Urisman et al [1]. However, this PCR setup also
failed to yield positive results. Furthermore, co-cultures of
activated PBMCs with XMRV permissive LNCaP cells yielded
neither free virus in the supernatants (RT assay) nor proviral DNA
in the LNCaP cells (nested PCR), despite the transmission of
XMRV from PBMCs to LNCaP cells having been documented
[7].
A very recent publication reports finding MLV-like gag
sequences in 32 out of 37 (86.5%) CFS patients and in 3 out of
44 (6.8%) healthy blood donors [29]. These sequences, amplified
from the DNA of unstimulated, uncultured PBMC using single
round or nested PCR with previously described XMRV primer
sets [1,7] were clearly distinct from XMRV, being more closely
related to modified-polytropic and polytropic murine endogenous
retroviruses than to XMRV itself. Although the selection of
primers for the nested PCR used in our study were primarily
guided by the sequences of known XMRV isolates, an alignment
with murine endogenous retroviruses genomes similar to the one
used by Urisman et al. [1] has been done to match with most
conserved regions in the pre-gag/gag region. Our intention was to
take advantage of the XMRV distinctive 24 nt deletion in this
region in order to discriminate between XMRV and other MLVs
on the size of the PCR product. According to sequence homology
our PCR set up should therefore amplify many of the known
polytropic, modified-polytropic and xenotropic proviruses in
addition to XMRV. Nevertheless, we can presently not formally
exclude that a proportion of the non-XMRV proviruses that have
been amplified in the report by Lo and co-workers [29] could have
been missed using our primer set.
The failure to detect XMRV in donor PBMCs prompted us to
test PBMCs from a subset of the CFS patients and healthy donors
for susceptibility to infection with the virus. Incubation with
XMRV from the persistently infected 22Rv1 cell line resulted in
the infection of all PBMC cultures. To avoid false-positive results
we also tested samples giving a positive XMRV signal for
contamination with murine genomic DNA or with plasmids
containing the VP62 molecular clone. Indeed, this was done for all
intentionally infected PBMC and LNCaP cultures and PBMC/
LNCaP co-cultures.
Although we did not ourselves investigate the phenotype of the
blood cells being infected with XMRV, Lombardi et al. have
reported the infection of T- and B-lymphocytes [7]. Infected blood
cells release only very low levels of virus, barely detectable with the
highly sensitive RT assay we used, whereas in contrast the
supernatants of infected LNCaP cells generally contained levels of
RT activity higher by 3 - 4 orders of magnitude. Nevertheless, one
week after infection, the supernatants from over half of the PMBC
cultures contained sufficient virus to infect LNCaP cells. The
relatively poor growth in PBMCs compared with that in the type I
IFN-insensitive LNCaP cells could due to a low LTR promoter
activity [30,31] and/or from the action of cellular antiretroviral
responses. It was recently reported that XMRV does not possess
countermeasures against the IFN-induced membrane protein
tetherin [32], and that therefore the release of virions from
human PBMC is probably inhibited by the action of this human
protein. Furthermore, this and other papers demonstrated that the
human protein APOBEC 3G, also expressed in human PBMC but
not in LNCaP cells, inhibits XMRV replication [32,33,34]. An
abundant particle production and rapidly spreading XMRV
infection in human PBMC cultures therefore seems unlikely and is
not supported by our data. Peripheral blood mononuclear cells are
preferred targets for many retroviruses including MLV and
additional experiments are needed to determine the precise
replication kinetics of XMRV in human PBMC cultures and the
subpopulation of blood cells involved.
Taken together we have used ELISA, sensitive PCR and co-
culture with permissive indicator cells in an attempt to detect
XMRV infection in cohorts of CFS and MS patients (with or
without MS related fatigue) and healthy controls. No evidence of
infection was found in any of the serum or activated PBMC
samples. However, we could confirm that PBMC cultures from
healthy donors and from CFS patients can be experimentally
infected with XMRV and produce transmissible virus.
Methods
Study population and specimen collection
CFS patients were diagnosed at the outpatient Clinic for Adult
Immunodeficiencies of the Dept. of Medical Immunology at the
Charite´ between 2007 and 2009. Diagnosis was based on a
thorough clinical evaluation of patients who had suffered from
sudden onset of severe fatigue for at least 6 months, had no
historical, laboratory or diagnostic evidence of exclusionary
medical, neurological or psychiatric disease and fulfilled the
Fukuda criteria (Fukuda 1994). A total of 39 CFS patients (13
males and 26 females, ranging from 17 to 56 years of age (median
age 41)) were included in the study.
MS patients were recruited from the Charite´’s NCRC
outpatient clinic. Neurological disability was assessed using
Kurtzke’s Expanded Disability Status Scale (EDSS) [35] (39 males
and 73 female patients, ranging from 20 to 54 years of age (mean
age 39); EDSS ranging from 0.0 to 6.0 (median EDSS 2.0)). All
patients had a defined relapsing remitting MS according to the
current panel criteria [27]. MS related fatigue, assessed using the
Fatigue Severity Scale (FSS [36]), was diagnosed in 56 of the 112
patients (median FSS score = 4.0 (range 1.0–7.0), with a score
above 4 defining fatigue).
Heparinized blood samples from patients and from age-
matched healthy donors (taken during the same period) were
processed to yield PB mononuclear cells (PBMC) by density
gradient centrifugation using Ficoll-Hypaque and cryopreserved
until analysis.
All patients gave written informed consent for the use of their
samples to test etiological theories of CFS and MS, respectively,
and the study was approved by the Ethics Committee of the
Charite - Universita¨tsmedizin Berlin.
Enzyme Linked Immunosorbent Assays
The solid phase ELISA for the detection of anti-XMRV Env
antibodies has been described elsewhere [5]. Briefly, bacterially
expressed and purified (via His-tag) XMRV envelope proteins
were coated overnight on Probind-96-well plates (Becton Dick-
inson Labware Europe, Le Pont de Claix, France) at room
temperature in equimolar amounts. The plates were blocked with
100 ml 2% Marvel milk powder in phosphate buffered saline (PBS)
for 2h at 37uC, washed three times with PBS containing 0.05%
Tween 20 (Serva, Heidelberg, Germany) and 50 ml mouse sera or
patient sera at a 1:200 dilution in PBS containing 2% milk powder
and 0.05% Tween 20 (PMT) were added to each well. After
incubation for 1 hour at 37uC, plates were washed three times and
50 ml of a 1:1000 dilution of a goat anti-mouse IgG-HRP
conjugate or goat anti-human IgG-HRP conjugate (both Sigma
Aldrich, Munich, Germany) in PMT was added. After further
incubation for 1 hour at 37uC, plates were washed three times and
50 ml substrate solution (0.6mg/ml ortho-phenylendiamin (OPD)
in 0.05 M phosphate-citrate buffer, pH 5.0 containing 0.4 ml/ml
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of a 30% hydrogen peroxide solution) was added. After 5–10
minutes the color development was stopped by the addition of
20 ml 1M sulfuric acid and the absorbance at 492nm was
measured using a microplate reader.
For detection of antibodies against XMRVGag a capture ELISA
was developed. 96-well plates were coated overnight with 0.3 mg per
well of purified monoclonal antibody R187 (kindly provided by N.
Fischer, Hamburg, Germany). A solution containing 25ng/well of
the C-terminal half of the recombinant XMRVGag protein [5] was
added. Plates were incubated for 1h and after washing three times
the sera samples were applied as described above. Goat polyclonal
antisera (kindly provided by B. Switzer, CDC, Atlanta, USA)
specific for MLV p30 and Friend MLV [17], detected with rabbit
anti-goat HRP conjugate (DAKO, Hamburg, Germany) at a
1:5000 dilution, were used to validate the assay.
Cell culture and antibody purification
The human prostate cancer cell line LNCaP (ATCC #CRL-
1740), the XMRV positive human prostate cancer cell line 22Rv1
[37] (ATCC #CRL-2505) and the MLV p30 specific antibody
producing hybridoma cell line R187 (ATCC #CRL-1912) were
grown in RPMI 1640 (Gibco) supplemented with 10% FCS
(Biochrome TPP). The HEK 293T cell line was grown in DMEM
(Gibco) supplemented with 10% FCS. Stored PBMC were thawed
and analyzed for viability by trypan exclusion staining. PBMC
were cultured in 6-well plates (16106 cells per ml) for seven days at
37uC in a humidified 5% CO2 atmosphere using Iscoves medium
(Biochrome Berlin, Germany) containing 10% AB serum or 20%
FCS, rhIL-2 (180 IU/ml, R&D Systems) and PHA (4 mg/ml).
For co-cultivation, 1ml suspensions of 16106 PBMC activated
for 3 days were added to 40–60% confluent LNCaP cells in 6-well
plates and removed 3h later by washing. LNCaP cells were
cultured for a further seven days in media without IL-2 and PHA
to avoid persistence of residual PBMC. Supernatants for
measurement of RT activity were taken on day 7.
Human PBMC were infected with XMRV-containing super-
natant from 22Rv1 cells. Briefly, fresh supernatant from 22Rv1
culture was centrifuged, sterile filtered and treated with RNase-
free DNase I (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions but omitting the final DNase heat-
inactivating step. This DNase treatment was included to avoid
possible carry-over of XMRV provirus-containing genomic DNA
from the 22Rv1 cells. One aliquot of the supernatant was heat
inactivated at 60uC for 1h and used as a control. 36106 PBMC
were pelleted and resuspended in 200 ml of the supernatants and
after 2h incubation at 37uC the cells were washed twice with PBS
and cultivated in 12-well plates for seven days.
Antibodies were purified from supernatant of R187 hybridoma
cells using a protein G Sepharose 4 Fast Flow column (GE
Healthcare Europe, Munich, Germany) according to the manu-
facturer’s instructions.
PCR
Tissue culture, DNA preparation and PCR testing were carried
out in different laboratories by different operators. Briefly, DNA
was extracted from PBMCs after seven days of cultivation with IL-
2 and PHA using the Qiagen Blood DNA Minikit (Qiagen,
Hilden, Germany), aliquoted and stored at 220uC. Nucleic acid
concentrations were determined using a Nanodrop device (Fisher
Scientific, Schwerte, Germany).
Diagnostic nested PCRs were performed as described elsewhere
[1,5] using 200ng –800ng template DNA per reaction and the
primer pairs Out-For (59-CCGTGTTCCCAATAAAGCCT-39)
and Out-Rev (59-TGACATCCACAGACTGGTTG-39) or In-For
(59-GCAGCCCTGGGAGACGTC-39) and In-Rev (59-CGGCG-
CGGTTTCGGCG-39), respectively The integrity of the DNA
samples was checked using a GAPDH PCR as described
previously [38]. The PCRs were run at least twice and by two
different operators in physically isolated rooms to avoid contam-
ination. In order to rule out the presence of potentially
contaminating VP62 plasmid DNA, a highly sensitive nested
PCR using forward primers within the pcDNA3.1 backbone
vector and reverse primers within XMRV was carried out.
Primers used for the outer PCR were CMV-For (59-AACC-
CACTGCTTACTGGCTTATCG-39) and In-Rev (59- CGGC-
GCGGTTTCGGCG -39), for the inner PCR T7-For (59- AA-
TACGACTCACTATAGGG -39) and Deletion-Rev (59- CCCCAA-
CAAAGCCACTCCAAAA -39). Conditions for the first round
PCR were 95uC/10min, 95uC/30sec, 60uC/30sec, 72uC/1min
for 20 cycles and a final elongation of 72uC/5min. Using 1/10th
(2.5 ml) of the first reaction the second round PCR was performed
as describe above but with an annealing temperature of 55uC and
for 35 cycles.
To screen for potential contamination with murine genomic
DNA a PCR designed to amplify a fragment of the rodent
mitochondrial DNA (D-loop) was also carried out. Primer
sequences CB1n (59-GGAGGMCARCCAGTWGAAYACC-
CATT-39) and 12S1n (59-TAATTATAAGGCCAGGACCA-
AACCT-39) were kindly provided by B. Klempa (Charite´, Berlin,
Germany) and PCR conditions were 95uC/10min, 95uC/30sec,
66uC/30sec, 72uC/1.5min for 35 cycles and a final elongation of
72uC/5min.
Immunofluorescence microscopy
Cells were grown on gelatine (0.3% coldwater fish gelatine in
distilled water) coated glass slides in 12-well plates and 24h after
seeding were transfected using Polyfect Reagent (Qiagen) with the
full length molecular clone pcDNA3-VP62 or with the pTH-
XMRV-coEnv or pTH-XMRV-coGAG plasmids containing
codon optimized synthetic full-length genes of the XMRV env or
gag under control of the CMV promoter. 48h after transfection the
cells were fixed with 2% formaldehyde (Sigma) in PBS and the
glass slides were placed upside-down on microscopy slides. Cells
were rinsed briefly in PBS, permeabilized with 0.5% Triton X-100
in PBS for 15 min and washed 3 times with PBS. After 30 min
incubation with blocking buffer (2% Marvel milk powder in PBS)
cells were incubated for 60 min at 37uC with the positive control
mouse Gag- or Env-antisera or human sera diluted 1:200 in
blocking buffer. The slides were washed extensively with PBS and
the secondary antibodies conjugated to fluorophores were added
for 30 min. After thorough washing steps with PBS, the cells were
mounted in Mowiol. Images were obtained on a Zeiss (LSM510)
confocal laser-scanning microscope.
RT activity assay
Quantification of type C retroviral reverse transcriptase activity
was performed using the Mn2+ C-type activity Kit (Cavidi,
Uppsala, Sweden) according to the manufacturer’s instructions.
Specific RT activity and background were determined using the
Mn2+ reverse transcriptase supplied with the kit. Cell culture
supernatants were sampled on the days stated and remaining cells
or debris removed by centrifugation. Samples were stored at
280uC before being thawed and tested in (at least) duplicate.
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